rutgers pharmaceutical industry fellowship program · 2020-02-25 · vision and a mission to save...

2019 - 2020

RUTGERS PHARMACEUTICAL

INDUSTRY FELLOWSHIP PROGRAM

In partnership with

A MESSAGE FROM

LEADERSHIP On behalf of Merck & Co., and the Ernest Mario School of

Pharmacy at Rutgers University, thank you for express-

ing your interest in the Pharmaceutical Industry Fellow-

ship Program. As you move forward in your career, I en-

courage you to consider the fellowship opportunities at

Merck.

Led by former fellows and senior members of the man-

agement team, Merck Research Laboratories (MRL) has

designed two-year fellowship programs that will offer

you a tremendous opportunity to learn, grow, and be

part of a dynamic and exciting culture in the areas of

Translational Medicine, Clinical Sciences and Study Man-

agement, Clinical Safety & Risk Management, Global

Regulatory Affairs, Global Medical Affairs, Global Medical

Information and Quantitative Pharmacology and Phar-

macometrics (QP2). We believe these critical areas in the

drug development process offer fellows a unique oppor-

tunity to build skills and gain hands on experience that

will be invaluable as they pursue a rewarding career in the

pharmaceutical industry.

We have a strong commitment to continually develop a

program that can generate success for you, Rutgers Uni-

versity, and Merck. We recognize that you are among the

best and the brightest coming out of pharmacy school,

bringing a strong track record of high achievement. Our

program is designed to allow you to continue your suc-

cess in a post-doctoral environment and for us to work

with and train the potential leaders of tomorrow.

The fellowship program at Merck is occurring at an excit-

ing time as we have the most powerful R&D engine in our

company’s history. Merck is a strong and diverse compa-

ny with an extensive global reach. We have a broad pipe-

line, a number of products to help people, and we are

more passionate than ever about what matters most to

our customers and the patients we serve.

At Merck, we see every employee as both a team mem-

ber and a potential leader with the power to influence

others through his or her actions. Our ability to excel de-

pends on the integrity, knowledge, imagination, skill, di-

versity, and teamwork of our employees. This fellowship

program is a component of our organizational focus on

people.

As many of you will learn from the Merck fellowship lead-

ership team during your interviews, we all take great

pride in our work and our business of improving human

health. We have an excellent program, and we’re looking

for exceptional candidates to become a part of that pro-

gram. I wish you the best of luck during the recruitment

process and hope you will strongly consider the unique

fellowship opportunities at Merck.

With Best Regards,

Roy D. Baynes, M.D., Ph.D.

Senior Vice President Global

Clinical Development Chief

Medical Officer

Merck Research Laboratories

CONTENTS

ABOUT MERCK

LEADERSHIP TEAM

MERCK RESEARCH LABORATORIES

FELLOWSHIPS

ALUMNI SPOTLIGHT

RUTGERS COMPONENT

ABOUT

MERCK HISTORY CULTURE PRODUCTS PHILANTHROPY

AT MERCK, WE ASPIRE TO SOLVE THE WORLD’S

CHALLENGES TO HEALTH AND WELL-BEING TO

ENSURE THE CONTINUITY OF HUMAN PROGRESS

WHAT WE DO

ENABLE

GENERATIONS

HOW WE DO IT

BRAVE

INVENTION

WHY IT MATTERS

ADVANCE

SOCIETY

1891

Leaving Darmstadt,

Germany, George

Merck arrives in New

York and establishes

Merck & Co, Inc.

1899

The Merck Manual

begins publication,

providing profession-

als with the best avail-

able medical

1933

The founder’s son,

George W. Merck,

launches

major new research

laboratories in Rah-

way, New Jersey, soon

leading to break-

throughs in vitamins,

antibiotics, and anes-

thetics.

1942

Merck’s penicillin “G” is

used in the first suc-

cessful treatment of

blood infection with

penicillin in the U.S.

Ramping up production

for the war earns

Merck the Army-Navy

“E” Award for excel-

1944

In collaboration with

Merck, Dr. Selman

Waksman of Rutgers

University produces

streptomycin, the

world’s first cure for

tuberculosis. Merck

waives the patent

1953

The merger with Sharp

& Dohme brings to

Merck important new

expertise in biological

and vaccine research

and global distribu-

1971

Measles, mumps, and

rubella virus vaccine is

launched in an innova-

tive combined form.

1986

Recombinant hepatitis

B vaccine is launched –

the first genetically

engineered vaccine

approved for humans,

and the first to prevent

1987

Ivermectin is devel-

oped for river blind-

ness and distributed

free to all who need it.

As of 1987, the compa-

ny has donated 2.5

million tablets

(estimated value of

$3.75 billion)

1996

Following a decade of

intensive research,

Merck’s protease inhib-

itor is approved for

treating HIV in just 45

days, one of the fastest

2006

The first vaccine to

prevent cervical can-

cer (the second-

leading cause of can-

cer deaths among

women worldwide) is

2006

The first DPP-4 inhibi-

tor for type 2 diabetes

is approved by the

FDA.

2009

The company and

Schering-Plough merge

to create

a stronger, more di-

verse global healthcare

2011

The company launches

the 10-year Merck for

Mothers initiative, a

global effort to bring

the issue of maternal

mortality to the fore-

front of global con-

2014

Helping people fight

cancer is our passion.

The first anti-PD-1 for

the treatment of ad-

vanced melanoma

receives approval for

2015

The Nobel Prize in

Medicine is awarded

to Dr. William Camp-

bell, one of the scien-

tists who discovered

avermectin, which

later led to the crea-

tion of ivermectin, the

key component of the

company’s revolution-

ary anti-river blindness

drug.

“We try to remember that medicine is for the patient. We try never to

forget that medicine is for the people. It is not for the profits.

The profits follow, and if we have remembered that, they have never

failed to appear. The better we have remembered it, the larger they

have been.”

George W. Merck, Merck President and Chairman 1925-1957

OUR INSPIRATION

We are inspired by a shared

vision and a mission to save and

improve lives.

We work with purpose, driven

by inventiveness and a passion

for excellence. Every breakthrough

we create has the potential to build a

healthier, more hopeful future for

people everywhere.

OUR MISSION

To discover, develop

and provide innovative

products and services that

save and improve lives

around the world.

OUR VISION

To make a difference

in the lives of people

globally through our

innovative medicines

and vaccines. We are

committed to being

the premier, research

intensive

biopharmaceutical

company and are

dedicated to

providing leading

innovations and

solutions for today

and the future.

OUR RESPONSIBILITY

We are committed to bringing a spirit of

invention to all that we do to help improve

health and well-being around the world to

expand access to health, operate ethically,

protect the environment and engage our

employees. It is our responsibility to address

the health needs of patients and society

through transformational science: delivering

vaccines and medicines that can help millions

around the world

CURRENTLY

PROMOTED PRODUCTS

OUR KEY INITIATIVES MERCK FOR MOTHERS

Our 10-year, $500 million initiative applies our scientific and business expertise to

reduce maternal deaths worldwide.

6,059,147 women in target countries have improved access to quality care. 12,170

providers/community health workers trained in target countries.

OUR COMMITMENT TO

END RIVER BLINDNESS More than 25 years ago, we committed to donate our medicine, Ivermectin — as much

as needed, for as long as needed — with the goal to help eliminate river blindness in

affected areas in Africa, Latin America and Yemen.

5.8 million dollars of direct investment in the program with 176 million treatments

approved. River blindness is now eliminated in Colombia, Ecuador and Mexico.

MSD-WELLCOME TRUST HILLEMAN LABORATORIES This first-of-its-kind, nonprofit, R&D joint venture is focused on creating new vac-

cines, and adapting existing vaccines for low-income countries.

Launched in 2009 with focus on low-cost vaccines treating a number of diseases.

MERCK FELLOWSHIP FOR GLOBAL HEALTH Our corporate pro bono program connects our employees with nonprofit organiza-

tions worldwide to help increase access to health services and to education in local

communities.

130 RTC fellows between 2012 and 2016 from 22 different countries worked with

33 nonprofit organizations.

LEADERSHIP TEAM

ABOUT

MERCK

LEADERSHIP

TEAM

MRL

FELLOWSHIPS

ALUMNI

SPOTLIGHT

RUTGERS

COMPONENT

EXECUTIVE SPONSORS

Ripal Shah, PharmD

Fellowship Director

Program Alumna

Director

Worldwide Regulatory Group

Gowri Murthy, PharmD, MBA

Professional Development Lead

Program Alumna

Director

Global Oncology Market Access

Sauzanne Khalilieh, PharmD

Fellowship Director

Program Alumna

Senior Principal Scientist

Translational Pharmacology

Eliav Barr, MD

Executive Sponsor

Senior Vice President

Global Medical Affairs

Eric Rubin, MD

Executive Sponsor


Clinical Research Oncology

Early Development

Jill DeSimone, B.S. Pharm

Executive Sponsor


US Oncology Commercial

Operations

LEADERSHIP TEAM

Kirolous Makarious, PharmD

Chief Fellow

Late Stage Clinical

Development - Oncology

James Young, PharmD

Chief Fellow

Late Stage Clinical

Development - Vaccines

Anne Flanigan-Minnick, PhD

Medical Affairs Fellowship Lead

Executive Director

Global Medical Information


MERCK RESEARCH

LABORATORIES FELLOWSHIPS ● Clinical Safety & Risk Management

● Late Stage Clinical Development

● Quantitative Pharmacology and

Pharmacometrics

● Global Regulatory Affairs

● Regulatory Affairs Advertising and

Promotion

● Regulatory Affairs International

● Translational Pharmacology

● Global Medical Affairs—Oncology

• Global Medical Information

• Global Scientific

Content

• Global Field

Medical Center

of Excellence

● U.S. Medical Affairs

Kelly Chambers, PharmD

Second Year Fellow

Samuel Kwarteng, PharmD

First Year Fellow

Suzanne Skarzynski, PharmD

Preceptor

Director

Clinical Safety & Risk Management

Liz Paschka, PharmD

Second Year Fellow

CLINICAL SAFETY & RISK

MANAGEMENT

CLINICAL SAFETY &

RISK MANAGEMENT Within the Global Regulatory Affairs and

Clinical Safety (GRACS), the Clinical Safety

& Risk Management (CSRM) department’s

mission is to improve public health by as-

suring the safe use of Merck products

worldwide through proactive safety as-

sessment, effective risk management, and

transparent risk communication through-

out the developmental and marketed

product life-cycle.

The goal of the CSRM fellowship is to pre-

pare the fellow for a career in pharma-

covigilance and risk management in the

pharmaceutical industry. This will be done

through a rigorous, hands-on training pro-

gram that exposes the fellow to the vari-

ous aspects of global product safety in an

industry setting.

Under the general direction and mentoring

of a CSRM Director, the fellow will develop

expertise in, and gradually assume greater

responsibility for, the overall clinical risk

management and safety surveillance of

assigned marketed products. The fellow

will learn about all aspects of safety sur-

veillance, including assessing safety infor-

mation, safety signaling, along with ensur-

ing completeness of that safety infor-

mation in worldwide package circulars. The

fellow will have joint responsibility for the

development of periodic safety update re-

ports and risk management plans and will

partner with appropriate Merck depart-

ments and therapeutic areas to ensure

efforts are aligned to meet our global risk

management strategies for assigned prod-

ucts. The fellowship will also involve work-

ing with the CSRM group to help develop

processes for the improved functioning of

the fellowship program, and implement

specific initiatives to achieve identified

goals.

The fellow will have the opportunity to in-

teract with other departments within

Merck, such as Medical Affairs, Epidemiol-

ogy, Clinical Research, Biostatistics, and

Regulatory Affairs to learn how Clinical

Safety & Risk Management is incorporated

throughout the organization. Additionally,

the fellow will learn how pharmaceutical

manufacturers use data to support re-

search, development, approval, and access

for new therapeutic products.

ABOUT

MERCK

LEADERSHIP

TEAM

MRL

FELLOWSHIPS

ALUMNI

SPOTLIGHT

RUTGERS

COMPONENT

Deborah Brown

Preceptor

Associate Principal Scientist

Clinical Sciences & Study Management

Michelle Chawla, PharmD

Second Year Fellow

LATE STAGE

CLINICAL DEVELOPMENT

Kirolous Makarious, PharmD

Second Year Fellow

Chief Fellow

Mary-Gwen Miller, PharmD, MS

First Year Fellow

Suneet Degaonkar, PharmD

Second Year Fellow

Wyatt Chafin, PharmD

First Year Fellow

Kellie Celentano

Preceptor

Principal Scientist


Nicole Stauffer

Preceptor

Principal Scientist


Sandria De Sapio

Preceptor



Jacob Pyrzynski, PharmD

First Year Fellow

Mathew Boakye, PharmD

First Year Fellow

Saba Emami, PharmD, MS

Preceptor

Senior Scientist


LATE STAGE CLINICAL

DEVELOPMENT Global Clinical Trial Operations (GCTO) sup-

ports Merck’s Mission to discover, develop, and

provide innovative products and services that

save and improve lives around the world. Clini-

cal Sciences & Study Management (CSSM) is a

subfunctional unit within GCTO accountable for

all operational, technical, and scientific aspects

of headquarters-sponsored clinical trials, in-

cluding local registration trials and regulatory

commitments. The Clinical Scientist (CS)/

Study Manager (SM) fellow(s) will support the

scientific aspects of late stage clinical develop-

ment within therapeutic area of oncology as

well as play a key role in the operational plan-

ning and execution activities for our late stage

development clinical studies around the globe.

Through involvement and interaction with oth-

er functional areas, the fellow will become fa-

miliar with protocol design, scientific and oper-

ational oversight of trials, reporting trial re-

sults, and more. The fellow will serve as a core

member of a Clinical Trial Team (CTT) and col-

laborate with other functional areas including

Clinical Directors, Statistics, Regulatory

Affairs, Therapeutic Area Document Review

Committees, Data Management, Clinical Sup-

plies, and Regional Clinical Operations. The

principal goals of the Fellowship will be to pro-

vide an overview of the functional role of the

CS/SM in the drug development process, and

training opportunities aligned with the role of

the CS/SM at Merck.

The fellow has the opportunity to be involved

with study start-up, conduct, closeout, and

potentially registration activities.

Some of these activities include: study planning

and management, CTT leadership, protocol/

amendment authoring, case report form devel-

opment, budget management, protocol feasi-

bility, country selection, patient enrollment

projections, medical monitoring of clinical data,

trial tracking and reporting, program and study

communication, and clinical study reports and/

or publication authoring. The fellow will have

opportunities to interact with principal investi-

gators from top hospitals around the world and

to train site staff and Merck field personnel

about their protocol(s). Throughout the pro-

gram, the fellow will gain an advanced under-

standing of Good Clinical Practices, as well as

an exposure to the requirements for Investiga-

tional New Drug (IND) and New Drug Applica-

tion (NDA) submissions. Overall, the fellow will

have the chance to help advance Merck’s pipe-

line of innovative drug candidates so that they

might benefit people around the world.

*Not Pictured

ABOUT

MERCK

LEADERSHIP

TEAM

MRL

FELLOWSHIPS

ALUMNI

SPOTLIGHT

RUTGERS

COMPONENT

Kristen Pesci

Preceptor



Richard McFetridge

Preceptor

Principal Scientist


Irene Bae, PharmD

Second Year Fellow

Pavan Vaddady, PhD

Preceptor

Principal Scientist

Quantitative Pharmacology & Pharmacometrics

Joshua McAuley, PharmD

First Year Fellow

QUANTITATIVE PHARMACOLOGY

& PHARMACOMETRICS

Brian Maas, PharmD

Senior Scientist

Quantitative Pharmacology & Pharmacometrics

QUANTITATIVE PHARMACOLOGY

& PHARMACOMETRICS

Within the Department of Pharmacokinetics,

Pharmacodynamics, and Drug Metabolism, the

Quantitative Pharmacology and Pharmacomet-

rics (QP2) group is responsible for developing

and executing PK/PD and Modeling and Simu-

lation (M&S) strategies as a member of cross-

functional drug development teams. The group

applies functional area knowledge to answer

critical biologic, disease, and therapy related

questions spanning from drug discovery to

post-approval by optimizing model-based ap-

proaches.

QP2 scientists apply PK/PD and M&S ap-

proaches to design and evaluate clinical and

preclinical study data, characterize the kinetics

of drug absorption and disposition, assess the

dynamics of drug effect, and inform dose selec-

tion and go/no-go decisions. Our scientists also

maintain a comprehensive understanding of

global regulatory expectations for small mole-

cules and biologics, including authoring regula-

tory documents and representing the depart-

ment at regulatory meetings. The QP2 scien-

tist is a quantitative drug developer with a

strong, integrated understanding of the stra-

tegic elements of drug development across all

phases, applying quantitative methodologies

to impact all therapeutic areas.

In addition, QP2 scientists demonstrate out-

standing leadership, communication, and col-

laboration with key functional areas to create

an aligned, quantitative framework for impact-

ful decision making on drug development

teams.

This is accompanied in several key scientific

areas for QP2, including translational and clini-

cal PK/PD analyses, clinical trial simulations,

disease progression modeling, comparator

modeling and model-based meta analysis, ab-

sorption/biopharmaceutical modeling, adaptive

design, clinical utility indices, translation of bi-

omarkers to clinical outcomes, adherence mod-

eling, etc. This fellowship is particularly suited

to those looking for a research-based scientific

experience that leverages foundational science

and physiological principles to drive decision

making. This position is less focused on opera-

tional aspects of drug development. Through

involvement and interaction with other func-

tional areas, the fellow will also become familiar

with the application of PK/ PD and M&S in clin-

ical pharmacology and clinical research, regula-

tory policy, and scientific leader engagement in

various therapeutic areas.

ABOUT

MERCK

LEADERSHIP

TEAM

MRL

FELLOWSHIPS

ALUMNI

SPOTLIGHT

RUTGERS

COMPONENT

* Not recruiting for 2019-2020

GLOBAL REGULATORY

AFFAIRS

Jateh Major, PharmD

Senior Scientist

Global Regulatory Affairs Oncology

Tonja Hampton, MD

Preceptor

Director

Global Regulatory Affairs

GLOBAL REGULATORY

AFFAIRS As a part of Merck’s Global Regulatory

Affairs and Clinical Safety (GRACS) group,

Regulatory Affairs proactively provides regu-

latory expertise and strategic guidance in all

aspects of the drug development process in

order to ensure the production of quality

submissions that meet Health Authority re-

quirements and allow for expeditious review

and approvals. Regulatory Affairs is also re-

sponsible for maintaining marketed products

in compliance with regulatory requirements.

The focus of the two-year fellowship is in the

Therapeutic Area Liaison (TALs) group with-

in GRACS. This group is responsible for

providing regulatory strategic input in the

design of preclinical and clinical development

programs for all Merck pharmaceutical prod-

ucts (including in-licensed products). The

fellow can rotate between therapeutic areas

in order to experience and support key stra-

tegic regulatory milestones. The goal of the

TALs fellowship is to prepare the fellow for a

career in clinical/therapeutic regulatory

affairs in the pharmaceutical industry. This

will be done through a rigorous, hands-on

training program that exposes the fellow to

the various aspects of global regulatory

affairs in an industry setting.

Under the direction of a Director in TALs, the

fellow will act as a member of cross-

functional project teams and gain experience

in the development of global regulatory stra-

tegic plans, filing and/or strategic develop-

ment of regulatory dossiers, and routine and

complex requests from Health Authorities,

and will provide regulatory intelligence and

lead regulatory aspects of development mile-

stones.

The fellow will ensure that the content, or-

ganization, and quality of all regulatory docu-

mentation (i.e., INDs/IDDs, NDAs/MAAs,

supplements, variations, and responses to

questions and comments) are in compliance

with local and/or regional regulatory require-

ments and commitments. The fellow will

have the opportunity to interact with other

departments within Merck, such as Clinical

Research, CMC Regulatory (Chemistry, Man-

ufacturing and Controls), and Safety to learn

how global regulatory affairs is incorporated

throughout the organization.

The fellow and other members of TALs are

responsible for directing internal and exter-

nal activities aimed at meeting regulatory

requirements. As necessary, the fellow along

with Merck subject matter experts, including

regulatory, may interact with the U.S. FDA

and international regulatory agencies to dis-

cuss and agree on issues relating to develop-

ment programs and/or responses to Health

Authority questions. All representatives of

TALs also liaise with other Merck regulatory

personnel around the world.

ABOUT

MERCK

LEADERSHIP

TEAM

MRL

FELLOWSHIPS

ALUMNI

SPOTLIGHT

RUTGERS

COMPONENT

Lav Patel, PharmD

Second Year Fellow Rachel Henderson, PharmD, MS

Preceptor

Director

Office of Promotion and Advertising Review

REGULATORY AFFAIRS

ADVERTISING AND PROMOTION

REGULATORY AFFAIRS

ADVERTISING AND PROMOTION

As part of Merck’s Global Regulatory

Affairs and Clinical Safety (GRACS) group,

Regulatory Affairs proactively provides

regulatory expertise and strategic guid-

ance in all aspects of the drug development

process in order to ensure the production

of quality submissions that meet Health

Authority requirements and allow for ex-

peditious review and approvals. Regulato-

ry Affairs is also responsible for maintain-

ing marketed products in compliance with

regulatory requirements.

The focus of the two-year fellowship is in

the Office of Promotions and Advertising

Review (OPAR) group within GRACS. This

group is responsible for ensuring advertis-

ing and promotion materials are compliant

and accurately reflect the unique charac-

teristics which differentiate our products

and our company in the marketplace.

The fellow will have the opportunity to de-

velop an understanding of federal regula-

tions and guidance related to the promo-

tion of prescription drugs and biologics,

and to collaborate with a variety of func-

tions to ensure promotional activities are

compliant with regulations and corporate

policies.

In addition to the focus on promotion, the

fellow will be provided with exposure to

other departments within GRACS, such as

Regulatory Labeling and Worldwide Regu-

latory Group, to appreciate the role of

GRACS in prescription drug and biologic

development and maintenance.

The goal of the OPAR fellowship is to pre-

pare the fellow for a career in advertising

and promotion regulatory affairs in the

pharmaceutical industry. This will be done

through a rigorous, hands-on training pro-

gram in an industry setting.

ABOUT

MERCK

LEADERSHIP

TEAM

MRL

FELLOWSHIPS

ALUMNI

SPOTLIGHT

RUTGERS

COMPONENT

REGULATORY AFFAIRS

INTERNATIONAL

Mark Hanna, PharmD

First Year Fellow

Angela Lee, PharmD

First Year Fellow

REGULATORY AFFAIRS

INTERNATIONAL The focus of the two-year fellowship is in

the Regulatory Affairs International (RAI)

group within Merck’s Global Regulatory

Affairs and Clinical Safety (GRACS) group.

This group is responsible for providing

regulatory input in the execution of clini-

cal development programs for all Merck

pharmaceutical products (including in-

licensed products), support of new mar-

keting applications, for products that

have already been approved (in-line prod-

ucts). Under the direction of a Director in

RAI, the fellow will act as a member of

cross-functional project teams and gain

experience in the development of global

regulatory strategic plans. They will have

the opportunity to take part in the filing

and/or strategic development of regula-

tory dossiers, routine and complex re-

quests from Health Authorities, and will

provide regulatory intelligence and lead

regulatory aspects of development mile-

stones.

The fellow will ensure that the content, or-

ganization, and quality of all regulatory doc-

umentation (i.e., INDs/IDDs, NDAs/MAAs,

supplements, variations, and responses to

questions and comments) are in compliance

with local and/or regional regulatory re-

quirements and commitments.

The fellow will have the opportunity to in-

teract with other departments within

Merck, such as Clinical Research, CMC Reg-

ulatory (Chemistry, Manufacturing and

Controls), and CSRM (Clinical Safety and

Risk Management) to better understand

how regulatory affairs is incorporated

throughout the organization. In addition,

they will be responsible for directing inter-

nal and external activities aimed at meeting

regulatory requirements along with other

members of the RAI team. As necessary,

the fellow, along with Merck subject matter

experts, including regulatory, may interact

with the FDA and international regulatory

agencies to discuss issues relating to devel-

opment and in-line programs and/or re-

sponses to Health Authority questions. All

representatives of the RAI group also liaise

with other Merck regulatory personnel

around the world.

The goal of the RAI fellowship is to prepare

the fellow for a career in regulatory affairs in

the pharmaceutical industry. This will be

done through a rigorous, hands-on training

program that exposes the fellow to a variety

of functional areas where they will support

key strategic regulatory milestones.

* Not Pictured

ABOUT

MERCK

LEADERSHIP

TEAM

MRL

FELLOWSHIPS

ALUMNI

SPOTLIGHT

RUTGERS

COMPONENT

Cathy Hoath

Preceptor

Director

Global Regulatory Affairs, Vaccines

* Not recruiting for 2019-2020

Eric Kim, PharmD, MBA

Second Year Fellow

Sarah Hsieh, MD, MPH

Preceptor



Julia Spiridigliozzi, PharmD

Second Year Fellow

Andy Xu, PharmD

First Year Fellow

TRANSLATIONAL

PHARMACOLOGY

TRANSLATIONAL

PHARMACOLOGY

ABOUT

MERCK

LEADERSHIP

TEAM

MRL

FELLOWSHIPS

ALUMNI

SPOTLIGHT

RUTGERS

COMPONENT

Within the Department of Translational Medi-

cine (TM), the Translational Pharmacology

(TPharm) group is responsible for the conduct

of clinical trials. TPharm conducts the clinical

evaluation of the safety, pharmacokinetics

(PK), and pharmacodynamics (PD) of molecu-

lar and biological therapeutics in healthy sub-

jects and patient populations within the regu-

latory requirements for new investigational

products. The TPharm group includes the fol-

lowing divisions: TPharm Therapeutic Areas,

TPharm Clinical Operations (TPCO) and EU

Operations.

The TPharm Therapeutic Areas are aligned

with the Discovery Organization and include

Cardiovascular and Metabolic Diseases, Neu-

rology, Oncology, and Infectious Disease/

Vaccines/Inflammation. The mission of this

group is to discover new targets and bi-

omarkers based on causal human biology, de-

sign and conduct first in human (FIH) and clini-

cal proof of concept (PoC) studies, and build

novel clinical platforms to test therapeutic

hypothesis. TPharm conducts trials to evalu-

ate clinical pharmacology and support pro-

grams across the entire life cycle of a product

from FIH, through the development of novel

post-market formulations. TPCO provides

efficient operations support for all clinical tri-

als within TM, and the EU Operations group

conducts non-US trials to advance compounds

and establish safety and clinical PoC. Collec-

tively, TPharm provides all the preliminary

safety, PK and PD scientific support for the

progression into late stage clinical studies in

patients across all MRL therapeutic areas.

Within TPCO, the Early Clinical Scientist (ECS)

fellow will be responsible for developing proto

-cols, developing case report forms for data

col-lection, initiating studies, data monitoring,

data clean-up, and reporting of studies. The

focus of the investigations will be geared to-

ward the understanding of new molecular en-

tity safety and tolerability in healthy subjects

and patients, mechanism of action, PK, drug-

drug interactions, PD, as well as PoC.

The ECS fellow will be a member of Study

Teams and working groups where they will

collaborate with other functional area repre-

sentatives including Pharmacokinetics and

Drug Metabolism, Statistics, Data Manage-

ment, Clinical Supplies, and Regulatory

Affairs.

* Not Pictured

Randolph Matthews, MD, PhD

Preceptor



Adedayo Adedoyin, PhD

Preceptor

Principal Scientist


Wendy Ankrom, PhD

Preceptor

Principal Scientist


Yahya Rasoully, PharmD

Second Year Fellow

Lisa Kao, PharmD

Preceptor

Director, Global Medical

Information


Jena Patel, PharmD

First Year Fellow

Olivia Vanscoy, PharmD

First Year Fellow Punam Patel, PharmD

Second Year Fellow

Michael Vozniak, PharmD, BCOP

Preceptor

Director, Field Medical Alignment

US Oncology Global Medical Affairs

GLOBAL MEDICAL AFFAIRS—

ONCOLOGY

GLOBAL MEDICAL AFFAIRS—

ONCOLOGY

Global Medical Affairs (GMA), which is part of

Merck Research Laboratories (MRL), plays a crit-

ically important role in communicating about our

scientific program and advancing patient care.

We engage in peer-to-peer, bi-directional scien-

tific exchange with external stakeholders to im-

prove understanding of our company’s innova-

tive pipeline and licensed products. These ex-

changes also yield valuable insights, which we

share with our internal partners in Global Clinical

Development, Global Human Health and the

Center for Observational and Real-world Evi-

dence to help inform decision making regarding

product development, commercialization and life

-cycle management activities.

This 2-year fellowship provides a unique oppor-

tunity to focus in the oncology therapeutic area,

one of the most exciting areas of pharmaceutical

research and development. Individuals partici-

pating in this fellowship will gain a broad under-

standing of Medical Affairs through collaborative

leadership experiences in areas including Global

Medical Information (GMI), Global Scientific Con-

tent and Training (GSC and GST), Global & U.S.

Medical Strategy, and Field Medical.

GMA Oncology Fellows will expand their

knowledge by gaining exposure to a wide range

of oncology therapeutic areas including thoracic,

gastro-intestinal, genitourinary, women’s can-

cers, hematology, melanoma, and head and

neck.

During their first year, fellows will work primarily

in GMI on the Oncology Therapeutic Area Teams,

gaining solid foundational knowledge of their

assigned products and tumor types. Fellows will

become familiar with responding to unsolicited

Medical Information Requests (MIRs) and learn

how fair, balanced, and accurate responses are

developed and sent to customers. They will gain

experience in the medical review of promotional

materials for marketed products, learn how

training materials are developed/delivered, and

become involved in worldwide launch activities.

As a transition to their second year, fellows will

have the opportunity to work with the Global

Scientific Content team where they will learn to

collect insights from colleagues to assist in the

creation of reactive resources to help support

the company’s scientific communications, glob-

ally.

During their second year, fellows will integrate

into the rotational aspect of the fellowship and

will have the opportunity to rotate through mul-

tiple functional areas within Medical Affairs per

business need and personal interest. Rotational

opportunities include but are not limited to:

Global Scientific Training, Core Skills and Capa-

bilities, Global & U.S. Medical Strategy, Global

Operations, and Field Medical. Fellows will have

the opportunity to focus on scientific leader en-

gagements, collaborate with stakeholders within

the U.S. and around to the world to develop a

medical strategy plan, and proactively create

resources to support the field’s scientific ex-

change with scientific leaders.

ABOUT

MERCK

LEADERSHIP

TEAM

MRL

FELLOWSHIPS

ALUMNI

SPOTLIGHT

RUTGERS

COMPONENT

Tyler Stone, PharmD

Second Year Fellow

GLOBAL MEDICAL

INFORMATION

Frank Palumbo, PharmD

Preceptor

Director

Global Medical Information &


Janki Patel, PharmD

First Year Fellow

GLOBAL MEDICAL

INFORMATION Global Medical Information (GMI) is a criti-

cal part of Global Medical Affairs (GMA) at

Merck. GMA serves as a strategic partner,

providing high quality medical expertise to

the business and to our customers. GMA

helps to meet the needs of healthcare pro-

fessionals and organizations by generating

and communicating information that helps

them make informed choices that improve

health outcomes for patients.

GMI includes a diverse group of scientists

and healthcare professionals with a mis-

sion to:

• Customize/Create medical content

that is leveraged by Field Medical and

local Medical Information colleagues to

provide accurate and timely medical

information to unsolicited requests

from healthcare professionals, hospi-

tals, and managed care organizations

• Provide medically accurate review/

approval of US and Global advertising

and promotional materials created by

marketing/promotion, training, and

managed care

• Develop and deliver medical assets for

product and disease training

• Support launch activities around the

globe

GMI interacts cross-functionally and col-

laboratively with many departments, in-

cluding the Office of Promotion Advertis-

ing & Review (OPAR), Regulatory Affairs,

Learning and Development, Global Safety,

Clinical Research, Outcomes and Value-

Evidence, Legal, Compliance, Global Quali-

ty, the Merck Manufacturing Division, and

US and Global Marketing.

During this two-year Fellowship in GMI,

fellows will work in one or more key thera-

peutic areas. Fellows will become familiar

with responding to unsolicited Medical In-

formation Requests (MIRs) and learn how

fair-balanced and accurate responses are

developed and sent to customers. They will

gain experience in the medical review of

promotional materials for marketed/

investigational products, learn how train-

ing materials are developed/delivered, and

become involved in worldwide launch activ-

ities.

The Fellow in this Merck Rutgers program

will receive broad experience and exposure

across the GMA organization and beyond.

ABOUT

MERCK

LEADERSHIP

TEAM

MRL

FELLOWSHIPS

ALUMNI

SPOTLIGHT

RUTGERS

COMPONENT

GLOBAL SCIENTIFIC CONTENT

GLOBAL SCIENTIFIC

CONTENT Global Medical Affairs (GMA), which falls under

the Merck Research Laboratories (MRL) Divi-

sion, serves as a strategic partner to the fran-

chises and regions, providing high quality medi-

cal expertise to the business and to our custom-

ers. GMA helps to meet the needs of healthcare

professionals and organizations by generating

and communicating information that helps them

make informed choices that improve health out-

comes for patients. Global Scientific Content

(GSC) is a part of Global Medical Affairs Capabili-

ties (GMAC). GMAC’s mission is to drive and in-

novate world class Medical Affairs Capabilities,

to advance scientific exchange and enhance pa-

tient care. GSC includes a diverse group of scien-

tists and healthcare professionals focused on

strategic planning and scientific content devel-

opment for Global Medical Information and Field

Medical/Medical Scientific Liaisons (MSLs) use

worldwide.

The mission of GSC is to provide world-class,

global scientific content for use at the regional

and local levels.

Medical content developed by GSC is leveraged

by Field Medical, Global Medical Affairs and local

Medical Information colleagues to provide accu-

rate and timely medical information to unsolicit-

ed requests from healthcare professionals, hos-

pitals, and managed care organizations.

GSC supports launch activities around the globe

and interacts cross-functionally with many de-

partments, including Learning and Develop-

ment, Global Safety, Clinical Research, Legal,

Compliance, Global Quality, the Merck Manufac-

turing Division, and US and Global Marketing.

During the second year of the Fellowship, there

will be an opportunity for Fellows to work across

the GMAC organization- including but not lim-

ited to the Field Medical Center of Excellence

(FM CoE). The FM CoE is a function within Global

Medical Affairs Capabilities and is responsible for

creating tools, training, and resources focused

on advancing Field Medical capability of Merck

worldwide. Global Scientific Training is a primary

function within this team and this rotation would

expose the fellow to unique GST opportunities

such as the creation of a Global Scientific Train-

ing plan and execution of scientific training re-

sponsibilities. This includes creating disease

state modules, infographics, and interactive dig-

ital platforms through different channels con-

sistent with adult learning principles It encom-

passes working with colleagues across diverse

regions and markets and assessing and creating

curriculums that address their specific training

needs.

GSC fellow(s) will function within one of two

specific therapeutic areas - oncology or infec-

tious disease/vaccines.

The vision of Merck is to deliver breakthrough

innovations to extend and improve the lives of

people everywhere.

ABOUT

MERCK

LEADERSHIP

TEAM

MRL

FELLOWSHIPS

ALUMNI

SPOTLIGHT

RUTGERS

COMPONENT

Deborah Weiss, PharmD, MS,

RPh,BCACP

Preceptor

Sr. Specialist, Global Scientific Commu-nications Scientist

Global Medical Affairs Capabilities

Ciaran McCrory, PharmD

Preceptor

Director, Medical Affairs

Oncology Global Scientific Content

GLOBAL FIELD MEDICAL

CENTER OF EXCELLENCE

GLOBAL FIELD MEDICAL

CENTER OF EXCELLENCE The Global Field Medical Center of Excellence

(FM CoE) is a function within Global Medical

Affairs Capabilities (GMAC) that is responsible

for creating tools, training and/or processes

to strengthen the Field Medical capability of

Merck worldwide. Within the FM CoE resides

three functions which include: Global Scien-

tific Training (GST), Global Field Medical Excel-

lence, and Core Skills and Capabilities. The

Fellow’s primary role will be in Global Scientific

Training in Vaccines or Oncology, two thera-

peutic areas that are rapidly expanding across

the industry.

Global Scientific Training (GST): The Fellow

will join the Global Scientific Training team,

working either in Vaccines or Oncology, and

would be responsible for working with the

Global Medical Affairs Team to develop the

Global Scientific Training plan for our Field

Medical professionals around the world. He/

She would gain deep therapeutic knowledge,

while working cross-functionally with mem-

bers of the Global Medical Affairs team. The

cross collaboration required for such imple-

mentation would expose each fellow to a mul-

titude of stakeholders. Communications be-

tween Global Strategy, Content, Medical In-

formation and Field Medical Leadership are

routine and will foster a unique understanding

of various focal points within the pharmaceu-

tical industry. The Fellow would also gain an

understanding of policies and procedures re-

lated to training to ensure they understand

how to work compliantly.

The Fellow would gain skills and experiences

on how to work cross-functionally with mem-

bers of the Global Medical Affairs team to de-

velop and execute a Global Scientific Training

plan in their respective therapeutic area. The

Fellow would also gain experience working

globally through partnership with Medical

Affairs professionals across Merck’s affiliates

around the world.

Upon developing the GST plan, the Fellow will

support execution of the plan. This includes

delivering the training to field medical person-

nel via webinars, workshops, train the trainers

or the medical academy.

FM CoE Rotational Opportunities: In addition

to their primary responsibilities, the Fellow

will have the opportunity to rotate, or take on

projects within the other functions in the FM

CoE, including Core Skills and Capabilities and

Field Medical Excellence.

The FM CoE looks forward to welcoming these

Fellows into a dynamic, global role where they

will gain skills that will be foundational to a

career in the pharmaceutical industry.

ABOUT

MERCK

LEADERSHIP

TEAM

MRL

FELLOWSHIPS

ALUMNI

SPOTLIGHT

RUTGERS

COMPONENT

Lisa Vo Kholsa

Preceptor

Director, Global Scientific Training – Oncology

Kathleen Taylor

Preceptor

Director, Global Scientific Training – Vaccines

Marc Fares, PharmD

Second Year Fellow

U.S. MEDICAL AFFAIRS

Yoldine Meris, PharmD

First Year Fellow

U.S. MEDICAL AFFAIRS

US Medical Affairs (USMA) is a credible and trusted

partner to internal and external stakeholders, con-

ducting high-quality, peer-level scientific exchange and

research discussions with scientific leaders, investiga-

tors and key decision makers to advance clinical prac-

tice and bring benefit to patients. USMA Fellows will

have experiences across a range of therapeutic areas,

including cardiovascular and metabolic disease, neuro-

science, virology, infectious disease, oncology, and

anesthesia/surgery, as well as gain experience working

with Health Systems. They also will rotate through the

following functions in the OneGMA (One Global Medi-

cal Affairs) organization and in support of:

Field Medical function: Field Medical colleagues Re-

gional Medical Scientific Directors (RMSDs), and Health

Systems Medical Affairs Directors (HS MADs) are thera-

peutic area and disease experts, who engage in scien-

tific exchange with the external medical and scientific

community. RMSDs focus on specific therapeutic areas,

engaging with a range of scientific leaders, while HS

MADs provide cross-therapeutic support to decision

makers within payer and provider organizations across

the country. The Fellow will have the opportunity dur-

ing the field medical rotation to interact with Field

Medical colleagues and observe scientific and medical

discussions between Field Medical personnel and

members of the healthcare community.

Medical Affairs Therapeutic Areas: The Health Systems

Medical Affairs Strategy Leads (MASLs) and Regional

Directors of Medical Affairs (RDMAs) provide expert

scientific and medical leadership to Merck for each

therapeutic area to support the development of appro-

priate medical affairs strategies. MASLs and RDMAs

maintain relationships with internal stakeholders to

ensure strategic alignment of medical affairs activities.

MASLs and RDMAs also engage with external stake-

holders to obtain input that may inform the Medical

Affairs strategy. During the strategy rotation, the Fel-

low will work closely with MASLs and RDMAs to partici-

pate in the input gathering and strategic decision-

making process.

Global Scientific Content (GSC): GSC colleagues work

to provide Field Medical colleagues with approved

resources for medical and scientific training and for use

in scientific exchange with scientific leaders and key

decision makers. In the content rotation, the Fellow

will work under the guidance of GSC colleagues to help

drive the process of global medical and scientific con-

tent development, review and approval.

Operations: The Operations team is staffed by Project

Managers who work across functional areas within

Merck to drive the new and existing initiatives aligned

to the USMA strategies. Operations is responsible for

meeting management, communications, systems, re-

porting, training, and other key operational responsibil-

ities. The Fellow will have the opportunity to execute

cross-functional projects designed to help achieve US-

MA organizational objectives.

Global Professional Relations and Independent Medi-

cal Education (GPRIME): GPRIME managers establish

and maintain high quality relationships with profes-

sional societies to support educational efforts. The

GPRIME team is engaged in interactions with the lead-

ership of numerous patient advocacy groups, and pro-

fessional medical and pharmacy societies to drive inde-

pendent accredited medical education. Through the

GPRIME rotation, the Fellow will understand the inde-

pendent accredited education of health professionals

and learn about organizational relationships .

ABOUT

MERCK

LEADERSHIP

TEAM

MRL

FELLOWSHIPS

ALUMNI

SPOTLIGHT

RUTGERS

COMPONENT

* Not Pictured

Anne De Papp

Preceptor

Vice President, Medical Affairs

Dana Pico

Preceptor

Director, Medical Affairs

ALUMNI SPOTLIGHT

RUTGERS PHARMACEUTICAL

INDUSTRY FELLOWSHIP ALUMNI

Solomon Hassanzadeh, PharmD

Senior Scientist, Clinical Safety & Risk Management

Clinical Safety & Risk Management, Merck, Class of 2017

Suneri Shah, PharmD

Senior Clinical Scientist, Global Clinical Development

Late Stage Clinical Development, Merck, Class of 2017

Brittany Yan, PharmD

Global Medical Information Scientist

Global Medical Affairs, Merck, Class of 2016

Mujtaba Shahsamand, PharmD

Associate Principal Scientist, Clinical Safety & Risk Management


Brett Kritzberger, PharmD

Director, US Medical Affairs


Gowri Murthy, PharmD, MBA *

Director, Market Access Oncology

Early Clinical Research, Merck, Class of 2010

Ripal Shah, PharmD *

Director, Worldwide Regulatory Group

Global Regulatory Affairs, Merck, Class of 2009

Ripal Shah, PharmD

Associate Principal Scientist, Clinical Safety & Risk Management


Sauzanne Khalilieh, PharmD *

Senior Principal Scientist, Translational Pharmacology

Pharmacology, Novartis, Class of 1998

Victoria Lopomo, PharmD



Lindsey Sosnowski, PharmD

Associate Director, Oncology Global Medical Affairs

Oncology Global Medical Affairs, Merck, Class of 2018

Saba Emami, PharmD

Senior Scientist, Clinical Operations


Kezia Gravesande, PharmD

Clinical Scientist, Clinical Research

Translational Pharmacology, Merck, Class of 2018

Julian Kam, PharmD

Director, Oncology Global Medical Affairs


ABOUT

MERCK

LEADERSHIP

TEAM

RUTGERS

COMPONENT

ALUMNI

SPOTLIGHT

MRL

FELLOWSHIPS

* = Leadership Team

Laura Buckley, PharmD

Senior Specialist, Oncology Global Scientific Content


Jillian Cordero, PharmD


Clinical Safety & Risk Management , Merck, Class of 2019

Mari Ichimaru, PharmD

Senior Scientist, Clinical Operations

Late Stage Clinical Development , Merck, Class of 2019

Jateh Major, PharmD

Senior Scientist, Global Regulatory Affairs

Global Regulatory Affairs, Merck, Class of 2019

Nadia Noormohamed, PharmD

Senior Scientist, QP2

Quantitative Pharmacometrics, Merck, Class of 2019

Jesse Siegel, PharmD

Senior Scientist, Clinical Development


Abiola Ojo, PharmD



Anna Yang, PharmD



ALUMNI SPOTLIGHT

“As a post-doctoral fellow with Merck, I was provided the opportunity to work with many

talented and innovative mentors. The support of my mentors has allowed me to develop the

skills needed to be a successful professional in my area. Additionally, the Rutgers component

of the fellowship program allowed me to expand upon my leadership capacities and helped

further develop me as a professional.”

“Completing a 2-year Regulatory Affairs Fellowship established a strong foundation for my

career. My experiences opened my eyes to the many challenges in drug development and the

unique opportunities for pharmacists to be able to contribute to the pharmaceutical

industry.”

“The Post-Doctoral Fellowship Program at Merck provided me with the tools and skills

needed to jump-start my career in the pharmaceutical industry. The challenging and

rewarding experiences accelerated my professional development.”

“RPIF is an established and extensive program designed to introduce fellows into the pharma-

ceutical industry. Throughout my fellowship at Merck, I was involved in projects that advanced

my leadership abilities, functional expertise, and personal development. In this rapidly evolving

industry, the RPIF program prepares fellows to not only pursue a successful career, but be-

come leaders in their field.”

“The fellowship program provides a great opportunity for PharmD graduates to gain

experience and begin their careers in the pharmaceutical industry. As a fellow, I was

exposed to many challenging experiences, allowing me to gain the skills needed to

become a successful professional.”

ABOUT

MERCK

LEADERSHIP

TEAM

MRL

FELLOWSHIPS

ALUMNI

SPOTLIGHT

RUTGERS

COMPONENT

Solomon Hassanzadeh, PharmD

RPIF Class of 2017


Mujtaba Shahsamand, PharmD

RPIF Class of 2014


Victoria Lopomo, PharmD

RPIF Class of 2018


Ripal Shah, PharmD

RPIF Class of 2009

Global Regulatory Affairs

Mari Ichimaru, PharmD

RPIF Class of 2019


RUTGERS COMPONENT

ABOUT THE PROGRAM

PROGRAM HISTORY In 1984, at Rutgers, The State University of New Jersey, the

Ernest Mario School of Pharmacy and two pharmaceutical com-

panies began a collaborative pilot program to evaluate the po-

tential contributions of clinically-trained pharmacists within a

pharmaceutical industry practice setting. Following the suc-

cessful pilot, the Rutgers Pharmaceutical Industry Fellowship

(RPIF) Program grew significantly and expanded to include 21

companies within the pharmaceutical and biopharmaceutical

industries and over 200 fellows annually. In 2002, Dr. Ernest

Mario generously provided an endowment to establish the Insti-

tute for Pharmaceutical Industry Fellowships to enhance and

promote the role of pharmacists in industry through the RPIF

Program.

The Institute staff members:

• Provide leadership and administrative support

• Promote quality, communication, and scholarly activity

• Arrange specialized fellowship training opportunities within

the pharmaceutical and biopharmaceutical industries.

Recently In 2018, our program has expanded to offer interdisci-

plinary fellows' training by adding select physician fellowship

opportunities to our well-established program.

The RPIF Program has thrived under the leadership of the

founder, Dr. Joseph A. Barone, Dean and Professor II of the

Ernest Mario School of Pharmacy and Dr. Michael Toscani, Re-

search Professor and the Director for the Institute for Pharma-

ceutical Industry Fellowships.

2019 RPIF Program Certificate

More than 1000 post-doctoral fellows have completed the RPIF

Program, most of whom are pursuing influential and rewarding

careers in the pharmaceutical and biopharmaceutical industries

throughout the US and abroad. The RPIF Program has precep-

tors/mentors from industry who share their knowledge and

experiences with the fellows through an intense but closely-

guided training program. Assignments and projects are chal-

lenging, meaningful, and designed to enhance understanding of

the pharmaceutical and biopharmaceutical industries and the

fellow’s functional area.

Joseph A. Barone, Pharm.D, F.C.C.P.

Dean and Professor II

Ernest Mario School of Pharmacy

Michael Toscani, Pharm.D

Research Professor

Fellowship Director

Pharmaceutical Industry Fellowships

RUTGERS, THE STATE

UNIVERSITY OF NEW JERSEY

Rutgers, The State University of New Jersey, with approximately

70,875 students in its three campuses, is one of the major state

university systems in the United States.

ERNEST MARIO

SCHOOL OF PHARMACY

The New Jersey College of Pharmacy was founded in 1892 and was

incorporated into the University in 1927. The Ernest Mario School

of Pharmacy is part of Rutgers Biomedical and Health Sciences,

the only state school of pharmacy in New Jersey, with approxi-

mately 1,300 students in its Doctor of Pharmacy program. The

Rutgers Ernest Mario School of Pharmacy is located on the Univer-

sity’s main science and technology campus in Piscataway, New

Jersey. Because of its close proximity to the nation's leading phar-

maceutical and biopharmaceutical companies, the Ernest Mario

School of Pharmacy and the RPIF Program are uniquely capable of

providing fellows with advanced training in the pharmaceutical

and biopharmaceutical industries.

ABOUT

MERCK

LEADERSHIP

TEAM

MRL

FELLOWSHIPS

ALUMNI

SPOTLIGHT

RUTGERS

COMPONENT

KEY PROGRAM FEATURES

PROFESSIONAL

DEVELOPMENT SERIES All fellows gather at Rutgers once or twice monthly as a group to

participate in the Professional Development Day (PDD) Series, an

important component of their training that complements the

hands-on experience provided at the partner companies. The

PDDs are steered by a committee of fellows and are designed to

enhance the fellows’ presentation skills, emotional intelligence,

promote connectivity and a sense of community among fellows

from different companies and disciplines, develop new skill sets

under the guidance of external trainers, and provide general

knowledge about various aspects of drug development and issues

facing the pharmaceutical and biopharmaceutical industries.

The fellows learn from each other through individual and group

presentations and debates on topics and issues related to the

pharmaceutical and biopharmaceutical industries.

This dynamic forum provides an opportunity for open discussion

and debate among fellows, Rutgers faculty, and company precep-

tors. In addition, outside experts provide training and profession-

al development in a variety of areas (e.g., tools for corporate suc-

cess; professional writing, presentations, meeting facilitation,

negotiating, influencing, networking, and conflict resolution

skills; giving and receiving feedback; and business and dining eti-

quette). Other PDD guest speakers include senior industry exec-

utives, patient advocacy groups, and successful RPIF Program

alumni who share their insights and experiences. Importantly,

PDDs provide an excellent opportunity for fellows to interact with

each other and develop lasting personal friendships and a strong

professional network of fellows, faculty, alumni, and other indus-

try executives.

FOSTER

The Rutgers Pharmaceutical Industry Fellowship

Program FOSTERs the growth and development of

future pharmaceutical and biopharmaceutical indus-

try professionals through the following key program

features:

F O S T E R Family of Leading

Companies

Outstanding Alumni

Track Record

Strong Network The Pathway to

Industry

Enhanced Career

Path

Rigorous Academic

Component

Partners include

several of the

top 21 global

pharmaceutical and

biopharmaceutical

companies.

Over 1000 alumni

hold prominent

positions at many

leading companies.

Over 200 fellows

each year develop

valuable, lasting

connections with

each other, alumni,

preceptors, and

faculty.

Since 1984, the

Rutgers program has

been nationally

recognized, trusted,

and proven as the

pathway to industry

for pharmacists.

Increasingly chal-

lenging assignments

build depth of expe-

rienced and en-

hance the potential

for an accelerated

career path.

Rutgers affiliation

provides academic

and professional

development

opportunities.

APPLICATION PROCESS

AND ELIGIBILITY

Fellows for the Rutgers Pharmaceutical Industry Fel-

lowship Program are selected on a nationally-

competitive basis. Candidates must have completed a

Doctor of Pharmacy degree from an ACPE accredited

institution before July 1st of the fellowship term.

Participation in the ASHP Midyear Clinical Meeting/

PPS is strongly encouraged. Interested individuals

may submit their application materials (curriculum

vitae, three letters of recommendation and a letter of

intent) beginning November 23, 2019 and complete a

program interest form online by visiting our website

at: pharmafellows.rutgers.edu

All application materials must be submitted electroni-

cally, and applicants are strongly encouraged to sub-

mit the above documents by December 1st.

Please address your Letter of Intent & Letters of

Recommendation to :

Joseph A. Barone, Pharm.D., F.C.C.P.

Dean and Professor II


Rutgers, The State University of New Jersey

160 Frelinghuysen Road

Piscataway, NJ 08854-8020

Merck & Co., Inc.

2000 Galloping Hill Road

Kenilworth, NJ 07033

908.423.1000

www.merck.com


Rutgers, The State University of New Jersey

160 Frelinghuysen Road

Piscataway, NJ 08854-8020

The trademarks indicated by CAPITAL LETTERS in this publication are the property of, licensed to,

promoted or distributed by Merck & Co., Inc., its subsidiaries or related companies, except as noted.

As used in this publication, the terms “Merck” and the “Company” refer collectively to Merck & Co.,

Inc., the publicly held parent company, and its domestic and international subsidiaries, which are

engaged in the discovery, development, manufacturing and marketing of pharmaceutical and animal

health products.

rutgers pharmaceutical industry fellowship program · 2020-02-25 · vision and a mission to save...

Documents